<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Delayed treatment with <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> (NAm) reduces infarction induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in rats </plain></SENT>
<SENT sid="1" pm="."><plain>This study explored some potential mechanisms by which delayed NAm treatment may confer protection in the brain of Sprague-Dawley rats following permanent MCAO (pMCAO) </plain></SENT>
<SENT sid="2" pm="."><plain>NAm (500 mg/kg) or vehicle was given 2 h after the <z:hpo ids='HP_0003674'>onset</z:hpo> of pMCAO </plain></SENT>
<SENT sid="3" pm="."><plain>Cortical microperfusion, brain and rectal temperature were serially measured </plain></SENT>
<SENT sid="4" pm="."><plain>Neurobehavioral examinations were performed at 24 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> followed by sacrifice for histologic assessment </plain></SENT>
<SENT sid="5" pm="."><plain>Some rats were also sacrificed at 4 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> for analyses of ATP, <z:chebi fb="13" ids="16761">ADP</z:chebi>, <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>, and <z:chebi fb="3" ids="16335">adenosine</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Permanent MCAO induced spontaneous <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> and a sharp decrease in cortical microperfusion, ATP concentration, and the sum of <z:chebi fb="1" ids="16708">adenine</z:chebi> <z:chebi fb="9" ids="36976">nucleotides</z:chebi> (p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>At 4 h post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, NAm improved ATP recovery, the sum of <z:chebi fb="1" ids="16708">adenine</z:chebi> <z:chebi fb="9" ids="36976">nucleotides</z:chebi> (p &lt; 0.05) and attenuated the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced systemic <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> (p &lt; 0.05) without affecting brain temperature or cortical microperfusion </plain></SENT>
<SENT sid="8" pm="."><plain>At 24 h, NAm improved cortical microperfusion in the ischemic hemisphere and reduced total <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (p &lt; 0.05), but did not affect behavioral scores </plain></SENT>
<SENT sid="9" pm="."><plain>The data suggest that NAm attenuated brain damage following pMCAo initially by improving cerebral bioenergetic metabolism during the sub-<z:hpo ids='HP_0011009'>acute</z:hpo> phase of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, followed by a delayed improvement in microvascular perfusion </plain></SENT>
</text></document>